[Treatment of primary hyperlipoproteinaemia types, IIa, IIb, 3 and IV with clofibrate (author's transl)].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000553:Ambulatory Care; D000925:Anticoagulants / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001835:Body Weight; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008074:Lipoproteins / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010919:Placebos; D000637:Transaminases / Q000097:blood; D014280:Triglycerides / Q000097:blood
D000925:Anticoagulants; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol; D000637:Transaminases; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D002994:Clofibrate
Behandlung primärer Hyperlipoproteinämien der Typen IIa, IIB, 3 UND IV mit Clofibrat.